Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Merck Q4 net profit more than doubles
Thursday - 3/7/2013, 5:20am EST
AP Business Writer
FRANKFURT, Germany (AP) -- Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
The Darmstadt-based company said Thursday that its net profit rose to EUR272 million ($355 million), from EUR133 million in the same quarter the year before. Revenues rose 8 percent to EUR2.83 billion.
Merck was able to charge more for Rebif in the United States. For the full year, Rebif sales increased 7.5 percent to EUR1.89 billion. That offset slower sales growth for its Erbitux cancer drug.
The company benefited from leaving unprofitable lines of business and regions in its consumer health division, which overall saw lower sales but higher profits as the company focused its efforts and investments on more lucrative products and regions. It outsourced the manufacturing and packaging of its Seven Seas brand cod liver oil products in Britain, for instance.
Earnings also received a boost from its business in liquid crystal materials used in flat panel displays. The performance materials division, where the liquid crystal business provides the bulk of sales, saw revenues grow 21 percent in the fourth quarter. The division's numbers were boosted 7 percent for all of last year due to the dollar's stronger exchange rate with the euro, which magnifies euro earnings figures. The division gets the bulk of its sales in dollars.
For the full-year, profits decreased 7 percent to EUR567 million as the company took EUR504 million in non-repeating restructuring charges. Revenues rose 9 percent to EUR11.17 billion.
The company raised its dividend by 13 percent to EUR1.70 per share.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.